| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 30, 2021
Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has appointed a new executive leadership team. Ping Zhu,...
-
Aug 5, 2021
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Janna Hutz, Ph.D., as President of the Eisai Center for Genetics Guided Dementia Discovery...
-
Jun 28, 2021
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Andree Amelsberg, M.D., MBA, as Vice President, U.S. Medical Affairs, Oncology...
-
Apr 11, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its animation “Leave No One Behind-Disease of Neglected People” which features activities for the...
-
Feb 2, 2021Companies launch neurology-focused incubator at Eisai's G2D2 facility in Cambridge, Mass.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming...
